Extensive comments could buy industry time if FDA removes GRAS status from PHOs

摘要

If the FDA receives voluminous, detailed letters on the use of partially hydrogenated oils (PHOs), explaining the lengthy and difficult process required to reformulate products, it might delay revocation of the generally recognized as safe (GRAS) status of those ingredients, a former FDA official says.